ADH1A and cancer: Thus, ADH‐1, and ADH‐1‐like agents, may increase the delivery of other plasma protein‐bound anti‐cancer drugs to sites of tumor by increasing the permeability of tumor‐associated vasculature, thereby improving tumor response.